Psoriatic Arthritis with Peripheral Oligoarthritis (≤4 Swollen Joints) — What to Do After csDMARD Failure
This protocol applies to patients with psoriatic arthritis presenting as peripheral monoarthritis or oligoarthritis with ≤4 swollen joints and no poor prognostic features, who have not achieved adequate disease control with conventional synthetic DMARD therapy.
Clinical Scenario
Peripheral monoarthritis or oligoarthritis with ≤4 swollen joints, and none of the following poor prognostic factors:
Previous Treatment and Reason for Escalation
The prior treatment line used conventional synthetic DMARD therapy (methotrexate, leflunomide, or sulfasalazine) and did not achieve:
- At least 50% reduction in disease activity within 3 months
- Remission or low disease activity at 6 months
This protocol defines the recommended next step following that inadequate response.
Next-Line Treatment Approach
Treatment Targets
Improvement at 3 months; remission or low disease activity at 6 months, assessed by regular disease activity monitoring with therapy adjusted accordingly.
References
DOI: 10.1136/ard-2024-225531
- Patients with oligoarticular disease and lack of poor prognostic factors should also receive a csDMARD, but there is less urgency for these patients given the more favourable long-term prognosis.
- The latter may receive csDMARDs after a longer delay, and potentially a period of symptomatic treatment alone.
- In patients with peripheral arthritis and an inadequate response to at least one csDMARD, therapy with a bDMARD should be commenced.
- Regarding bDMARDs, no order of preference is given since no bDMARD has demonstrated superiority for joint involvement over other bDMARDs.
- Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.